These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 15121020

  • 1. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD.
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [Abstract] [Full Text] [Related]

  • 2. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
    Recker R, Stakkestad JA, Chesnut CH, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD.
    Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
    [Abstract] [Full Text] [Related]

  • 3. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH.
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [Abstract] [Full Text] [Related]

  • 9. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P, Ibandronate Intravenous Study Group.
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [Abstract] [Full Text] [Related]

  • 10. Beyond daily dosing: clinical experience.
    Cooper C.
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [Abstract] [Full Text] [Related]

  • 11. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY.
    Curr Pharm Des; 2005 Apr; 11(28):3711-28. PubMed ID: 16305506
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC, Bauss F.
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oral weekly ibandronate prevents bone loss in postmenopausal women.
    Tankó LB, Felsenberg D, Czerwiński E, Burdeska A, Jonkanski I, Hughes C, Christiansen C, Oral Ibandronate Group.
    J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
    [Abstract] [Full Text] [Related]

  • 16. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C.
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.